Article from the Symposium

You have full text access to this OnlineOpen article

Mechanisms of osteolytic bone metastases in breast carcinoma

  1. Sanna-Maria Käkönen Ph.D.,
  2. Gregory R. Mundy M.D.†,*

Article first published online: 23 JAN 2003

DOI: 10.1002/cncr.11132

Issue

Cancer

Cancer

Supplement: Skeletal Complications of Malignancy

Volume 97, Issue Supplement 3, pages 834–839, 1 February 2003

Additional Information

How to Cite

Käkönen, S.-M. and Mundy, G. R. (2003), Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer, 97: 834–839. doi: 10.1002/cncr.11132

Author Information

  1. University of Texas Health Science Center, Department of Molecular Medicine, Institute for Drug Development, San Antonio, Texas

  1. †

    Fax: (210) 567-3803

*Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900

Publication History

  1. Issue published online: 23 JAN 2003
  2. Article first published online: 23 JAN 2003
  3. Manuscript Accepted: 1 NOV 2002
  4. Manuscript Received: 15 JUL 2002

Funded by

  • National Institutes of Health. Grant Number: CA40035
  • U.S. Army Department of Defense. Grant Number: DAMD17-99-1-9403

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (102K)

REFERENCES

  • 1
    Fontana A, Delmas PD. Markers of bone turnover in bone metastases. Cancer. 2000; 88 (12 Suppl ): 2952–2960.
    Direct Link:
  • 2
    Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer. 2000; 88 (12 Suppl ): 2919–2926.
    Direct Link:
  • 3
    Mundy GR, Bertolini DR. Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol. 1986; 13: 291–299.
  • 4
    Liotta LA, Kohn E. Cancer invasion and metastases. JAMA. 1990; 263: 1123–1126.
  • 5
    Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889; 1: 571–573.
  • 6
    Zetter BR. The cellular basis of site-specific tumor metastasis. N Engl J Med. 1990; 322: 605–612.
  • 7
    Weiss L, Orr FW, Honn KV. Interactions between cancer cells and the microvasculature: a rate-regulator for metastasis. Clin Exp Metastasis. 1989; 7: 127–167.
  • 8
    Liotta LA, Mandler R, Murano G, et al. Tumor cell autocrine motility factor. Proc Natl Acad Sci USA. 1986; 83: 3302–3306.
  • 9
    Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980; 284: 67–68.
  • 10
    Boyde A, Maconnachie E, Reid SA, Delling G, Mundy GR. Scanning electron microscopy in bone pathology: review of methods, potential and applications. Scan Electron Microsc. 1986; 4: 1537–1554.
  • 11
    Eilon G, Mundy GR. Direct resorption of bone by human breast cancer cells in vitro. Nature. 1978; 276: 726–728.
  • 12
    Moseley JM, Kubota M, Diefenbach-Jagger H, et al. Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci. 1987; 84: 5048–5052.
  • 13
    Powell GJ, Southby J, Danks JA, et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res. 1991; 51: 3059–3061.
  • 14
    Southby J, Kissin MW, Danks JA, et al. Immunohistochemical localization of parathyroid hormone-related protein in breast cancer. Cancer Res. 1990; 50: 7710–7716.
  • 15
    van der Pluijm G, Sijmons B, Vloedgraven H, Deckers M, Papapoulos S, Lowik C. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J Bone Miner Res. 2001; 16: 1077–1091.
    Direct Link:
  • 16
    Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in breast cancer-mediated osteolysis. J Clin Invest. 1996; 98: 1544–1548.
  • 17
    Miki T, Yano S, Hanabuchi M, Sone S. Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice. Oncol Res. 2001; 12: 209–217.
  • 18
    Pfeilschifter J, Mundy GR. Modulation of transforming growth factor beta activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci USA. 1987; 84: 2024–2028.
  • 19
    Yin JJ, Selander K, Chirgwin JM, et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999; 103: 197–206.
  • 20
    Käkönen S, Selander KS, Chirgwin JM, et al. TGF-β stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem. In press.
  • 21
    Miyazono K, ten Dijke P, Heldin CH. TGF-beta signaling by Smad proteins. Adv Immunol. 2000; 75: 115–157.
  • 22
    Zimmerman CM, Padgett RW. Transforming growth factor beta signaling mediators and modulators. Gene. 2000; 249: 17–30.
  • 23
    Wrana JL, Attisano L. The Smad pathway. Cytokine Growth Factor Rev. 2000; 11: 5–13.
  • 24
    Hanafusa H, Ninomiya-Tsuji J, Masuyama N, et al. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression. J Biol Chem. 1999; 274: 27161–27167.
  • 25
    Mulder KM. Role of Ras and Mapks in TGF beta signaling. Cytokine Growth Factor Rev. 2000; 11: 23–35.
  • 26
    Kakonen S, Neal M, Chirgwin JM, et al. Transforming growth factor-beta (TGF-β) stimulates tumor parathyroid hormone-related protein (PTHrP) production via mitogen activated protein (MAP) kinase pathways in a cell-specific manner. Calcif Tissue Int. 2001; 66 (Suppl 1): S62.
  • 27
    Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 1999; 140: 4451–4458.
  • 28
    Kong YY, Yoshida H, Sarosi T, et al. OPGL is a key regulator on osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999; 397: 315–323.
  • 29
    Lee SK, Lorenzo, JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology. 1999; 140: 3552–3561.
  • 30
    Grosfeld JL, Du X, Williams DA. Interleukin-11: its biology and prospects for clinical use. JPEN J Parenter Enteral Nutr. 1999; 23: S67–69.
  • 31
    Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc Natl Acad Sci USA. 1993; 90: 11924–11928.
  • 32
    Hughes FJ, Howells GJ. Interleukin-11 inhibits bone formation in vitro. Calcif Tissue Int. 1993; 53: 362–364.
  • 33
    Lacroix M, Siwek B, Marie PJ, Body JJ. Production and regulation of interleukin-11 by breast cancer cells. Cancer Lett. 1998; 127: 29–35.
  • 34
    Morinaga Y, Fujita N, Ohishi K, Tsuruo T. Stimulation of interleukin-11 production from osteoblast-like cells by transforming growth factor-beta and tumor cell factors. Int J Cancer. 1997; 71: 422–428.
    Direct Link:
  • 35
    Zhang Y, Fujita N, Oh-hara T, et al. Production of interleukin-11 in bone-derived endothelial cells and its role in the formation of osteolytic bone metastasis. Oncogene. 1998; 16: 693–703.
  • 36
    Kakonen S, Selander KS, Carreon MR, et al. TGFβ signaling in osteolytic cancer cell lines: stimulation of IL-6, IL-11, PTHrP, and VEGF through MAP kinase pathways. J Bone Miner Res. 2001; 16 (Suppl 1): S454.
  • 37
    Elias JA, Tang W, Horowitz MC. Cytokine and hormonal stimulation of human osteosarcoma interleukin-11 production. Endocrinology. 1995; 136: 489–498.
  • 38
    Selander KS, Reddi S, Harris KW, et al. Increased interleukin-11 expression by breast cancer cells results in increased bone metastases in mice. Calcif Tissue Int. 2000; 66 (Suppl 1): S68.
  • 39
    Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 2001; 107: 1235–1244.
  • 40
    Chikatsu N, Takeuchi Y, Tamura Y, et al. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun. 2000; 26: 632–637.
  • 41
    Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest. 1997; 99: 2509–2517.
  • 42
    Lee J, Weber M, Mejia S, Bone E, Watson P, Orr W. A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. Eur J Cancer. 2001; 37: 106–113.
  • 43
    De La Mata J, Uy H, Guise TA, et al. IL-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest. 1995; 95: 2846–2852.
  • 44
    Uy HL, Mundy GR, Boyce BF, et al. Tumor necrosis factor enhances parathyroid hormone related protein (PTH-rP)-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. Cancer Res. 1997; 57: 3194–3199.
  • 45
    Guise TA, Yoneda T, Yates AJ, Mundy GR. The combined effect of tumor-produced parathyroid hormone-related protein and transforming growth factor alpha enhance hypercalcemia in vivo and bone resorption in vitro. J Clin Endocrinol Metab. 1993; 77: 40–45.
  • 46
    Sanders JL, Chattopadhyay N, Kifor O, Yamaguchi T, Brown EM. Extracellular calcium-sensing receptor (CaR) expression and its potential role in parathyroid hormone-related peptide (PTHrP) secretion in the H-500 rat Leydig cell model of humoral hypercalcemia of malignancy. Biochem Biophys Res Commun. 2000; 269: 427–432.
  • 47
    Buchs N, Manen D, Bonjour JP, Rizzoli R. Calcium stimulates parathyroid hormone-related protein production in Leydig tumor cells through a putative cation-sensing mechanism. Eur J Endocrinol. 2000; 142: 500–505.
  • 48
    Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M. Growth factors in bone matrix. J Biol Chem. 1986; 261: 12665–12674.
  • 49
    Zakalik D, Diep D, Hooks MA, Nissenson RA, Strewler GJ. Transforming growth factor beta increases stability of parathyroid hormone related protein messenger RNA. J Bone Miner Res. 1992; 7 (Suppl 1): 104.
  • 50
    Kiriyama T, Gillespie MT, Glatz JA, Fukumoto S, Moseley JM, Martin TJ. Transforming growth factorα stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator? Mol Cell Endocrinol. 1992; 92: 55–62.
  • 51
    Merryman JI, DeWille JW, Werkmeister JR, Capen CC, Rosol TJ. Effects of transforming growth factor β on parathyroid hormone-related protein production and ribonucleic acid expression by a squamous carcinoma cell line in vitro. Endocrinology. 1994; 134: 2424–2433.
View Full Article (HTML) Get PDF (102K)